Your Article Summary
See Latest ArticlesCaspofungin for the treatment of candidaemia in patients with haematological malignancies
Clinical Microbiology and Infection, 07/01/09
Pagano L et al. - In a study to evaluate the efficacy of caspofungin in neutropenic pts with haematological malignancies (HM) and candidaemia, results suggest that treatment of candidaemia with caspofungin in neutropenic HM was efficacious, as it is in non-haematological subgroups.
Methods- This study was prospectively conducted in 11 haematology divisions over a 2-yr period to evaluate the efficacy of caspofungin in 24 neutropenic pts with haematological malignancies (HM) and candidaemia.
- Pts had received chemotherapy for HM and were neutropenic (PNN < 0.5 x 109/L) for a median of 12 days (2–41) before candidaemia.
- Pts received caspofungin for a median duration of 12 days, obtaining a favourable overall response of 58%.
- At 30 days, 11 pts had died (46%); candidaemia was responsible for mortality in 6 pts (25%).
Related Articles
A rescue therapy with a combination of caspofungin and liposomal amphotericin B or voriconazole in children with haematological malignancy and refractory invasive fungal infections
Mycoses, 11/12/09
Relevance Score: 80%
Continuous infusion of amphotericin B deoxycholate: an innovative, low-cost strategy in antifungal treatment
Mycoses, 10/29/09
Relevance Score: 80%
Characteristics of Candida albicans Biofilms Grown in a Synthetic Urine Medium
Journal of Clinical Microbiology, 10/08/09
Relevance Score: 80%
Candidiasis: New agents for invasive infections
The Clinical Advisor, 10/06/09
Relevance Score: 77%
Today in Leukemia/Lymphoma...keeping you current
Receive free subspecialty "5-minute updates" via email
Concurrent diagnoses of Hodgkin lymphoma and biclonal myeloma in the bone marrow
Annals of Diagnostic Pathology, 12/04/09
Clinical Features and Treatment Outcomes of Non-Hodgkin's Lymphomas Involving Rare Extranodal Sites: A Single-Center Experience
Acta Haematologica, 12/04/09
Phase I Clinical and Pharmacokinetic Study of Oral Sapacitabine in Patients With Acute Leukemia and Myelodysplastic Syndrome
Journal of Clinical Oncology, 12/04/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Management of patients with advanced bladder cancer following major response to systemic chemotherapy
Expert Review of Anticancer Therapy, 12/04/09
ML17032 trial: capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in advanced gastric cancer
Expert Review of Anticancer Therapy, 12/04/09
Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer
Expert Review of Anticancer Therapy, 12/04/09